Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

U.S. CDC says all adults should get COVID-19 booster shots

11/29/2021 | 04:37pm EST

Nov 29 (Reuters) - The U.S. Centers for Disease Control and Prevention (CDC) said on Monday everyone aged 18 years and older should get a booster shot, as it looks to tackle a new and highly infectious strain of the coronavirus that is quickly spreading across the globe.

The update comes after President Joe Biden on Monday called for wider vaccination to curb the spread of the Omicron coronavirus variant, which was first detected in southern Africa.

The U.S. health regulators last week expanded the eligibility for booster shots of COVID-19 vaccines to all adults aged 18 and older either six months after their initial Pfizer or Moderna vaccine doses or two months after their Johnson & Johnson shot.

The CDC had, however, stopped short of saying all adults aged 18 to 49 should get the additional shots.

The agency is taking a more cautious stance as Omicron's emergence further emphasizes the importance of vaccination and boosters, CDC Director Rochelle Walensky said in a statement on Monday.

Amid the renewed emphasis, Pfizer and partner BioNTech are expected to ask the U.S. Food and Drug Administration (FDA) in the coming days to authorize their booster shots for those aged 16 and 17 years, the Washington Post reported on Monday, citing sources.

Separately, the Wall Street Journal reported https://on.wsj.com/3E5Mgvq that the FDA could approve booster doses for 16 and 17 year-olds as soon as next week.

Pfizer, BioNTech and the FDA did not respond to Reuters' requests for comment.

Omicron, which the World Health Organization said carried a very high risk for fueling infection surges, has now been confirmed in several countries including Germany, Hong Kong, South Africa and Canada.

Scientists in the United States and around the world are urgently examining vaccine effectiveness related to this variant, the CDC said.

The agency also said the 47 million adults who are not yet vaccinated are encouraged to get vaccinated as soon as possible. (Reporting by Manojna Maddipatla in Bengaluru; additional reporting by Shubham Kalia; Editing by Amy Caren Daniel and Rashmi Aich)


ę Reuters 2021
All news about MODERNA, INC.
11:43aModerna says aims to name 'country of choice' for COVID vaccine production in Africa so..
RE
06:49aEMA Says Spikevax Product Information To Be Updated To Include Paraesthesia As Rare Sid..
RE
06:47aEMA : Assessment of whether vaccination can cause capillary leak syndrome (is ongoing for ..
RE
01/19Prior COVID infection more protective than vaccination during Delta surge, U.S. study f..
RE
01/19Valneva Shares Suffer as Coronavirus Vaccine Seen Arriving Too Late
DJ
01/18US Stocks Slump as Treasury Yields Hit 2-Year High, Goldman Sachs Weighs on Financials
MT
01/18US Stocks Start Week Lower as Treasury Yields Hit 2-Year High, Goldman Sachs Weighs on ..
MT
01/18Morgan Stanley Adjusts Moderna Price Target to $315 From $313, Maintains Equal Weight R..
MT
01/18Equities Slump Midday After Treasury Yields Touch Two-Year High, Goldman's Earnings Mis..
MT
01/18MIDDAY REPORT : US Stocks Slump After Treasury Yields Touch Two-Year High; Goldman's Earni..
MT
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 17 520 M - -
Net income 2021 11 079 M - -
Net cash 2021 9 774 M - -
P/E ratio 2021 6,59x
Yield 2021 -
Capitalization 70 577 M 70 577 M -
EV / Sales 2021 3,47x
EV / Sales 2022 2,36x
Nbr of Employees 1 300
Free-Float 90,5%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MRNA | US60770K1079 | MarketScreener
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 19
Last Close Price 174,07 $
Average target price 273,19 $
Spread / Average Target 56,9%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-31.46%70 577
LONZA GROUP AG-14.10%53 088
IQVIA HOLDINGS INC.-14.84%45 903
SEAGEN INC.-14.26%24 238
ICON PUBLIC LIMITED COMPANY-17.00%20 923
CELLTRION, INC.-16.67%19 573